To investigate the pharmacological mechanisms underlying the induction of thermogenesis by Metabolite 2 (M2; BTS 54 505), a major pharmacologically active metabolite of the anti-obesity drug, sibutramine. DESIGN: Adult female Wistar rats were treated with M2 or vehicle, with or without various monoamine receptor antagonists, prazosin, RS79948, metergoline, propranolol and ( þ )butaclamol. MEASUREMENTS: Colonic temperature and food intake at room temperature (21 AE 1 C), thermoregulatory behavioural response, operant responding for exogenous heat at 7 8 C and oxygen consumption at thermoneutrality (29 C). RESULTS: M2 (10 mg=kg, p.o.) significantly increased colonic temperature during the 4.5 h period following drug administration. This effect was abolished by the non-selective 5-HT receptor antagonist, metergoline (1 mg=kg, p.o.), and a 1 -adrenoceptor antagonist, prazosin (1 mg=kg, p.o.), measured at 1.5 -2.5 h post-M2 administration, and was partially antagonized by each antagonist at 3.5 -4.5 h. The non-selective b-adrenoceptor antagonist, propranolol (1 mg=kg, p.o.), had no effect on the M2-induced increase in colonic temperature, whereas at 20 mg=kg (p.o.), propranolol partially inhibited the effect of M2 on colonic temperature. By contrast, the selective a 2 -adrenoceptor antagonist, RS79948 (1 mg=kg, p.o.), and the D2=D1 receptor antagonist, ( þ )butaclamol (200 mg=kg, p.o.), did not alter the effect of M2 on colonic temperature. In the thermoregulatory study, M2 (10 mg=kg, i.p.)-treated rats required significantly less radiant heat at 7 8 C to maintain body temperature, and this effect was not affected by the D2=D1 receptor antagonist ( þ )butaclamol (100 mg=kg 71 , i.p.). The hypophagia induced by M2 (10 mg=kg) measured up to 24 h was partially antagonized by the a 1 -adrenoceptor antagonist, prazosin, whereas metergoline, RS79948, propranolol and ( þ )butaclamol had no effect on M2-induced hypophagia. CONCLUSION: It is concluded that 5-HT, a 1 -and b 3 -adrenoceptors are involved in the induction of thermogenesis by M2, whereas the hypophagic effect is mainly mediated via a 1 -adrenoceptors. These findings are consistent with M2 increasing 5-HT and noradrenaline tone via potent reuptake inhibition which subsequently results in increased efferent sympathetic activity to brown adipose tissue (BAT).
Introduction
Sibutramine is a novel, centrally-acting anti-obesity drug that produces its effects on energy balance via potent inhibition of 5-hydroxytryptamine (5-HT, serotonin) and noradrenaline (NA) reuptake in vivo. 1 -3 Sibutramine (N-[1-[1-(4-chlorophenyl)cyclobutyl]-3-methybutyl]-N,N-dimethylamine hydrochloride monohydrate) is a tertiary amine that is rapidly demethylated in animals and man to yield the secondary amine (Metabolite 1; BTS 54 354; N-[1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl]-N-methylamine hydrochloride) and the primary amine (Metabolite 2; BTS 54 505; 1-[1-(4-chlorphenyl)cyclobutyl]-3-methylbutylamine hydrochloride). Studies in vitro using rat brain synaptosomes show that sibutramine is a weak inhibitor of NA and 5-HT reuptake, whereas Metabolites 1 and 2 (M1 and M2) are potent reuptake inhibitors with approximately equal potency to the selective NA reuptake inhibitor, desipramine, and the selective 5-HT reuptake inhibitor, fluoxetine. 4, 5 It has been further demonstrated that the monoamine uptake inhibition properties of sibutramine in vivo are predominantly mediated by its primary and secondary metabolites. 6 Animal studies have shown that sibutramine reduces food intake in rats when given acutely 7 -9 by enhancing the natural process of satiety. 10, 11 Evidence from various studies with selective monoamine reuptake inhibitors and receptor antagonists indicates that hypophagia probably results from 5-HT and NA reuptake inhibition in the CNS. 3, 7, 8 Sibutramine has also been shown to cause prolonged weight-loss in rats 12 and weight-loss and weight maintenance in patients for periods of up to 2 y. 13 -15 The ability of sibutramine to cause weight-loss in animals and humans was initially ascribed to its effect on food intake. However, in a chronic study of obese Zucker rats, 16 it was found that, although sibutramine produced an initial, significant decrease of food intake, the average intake was not significantly lower in the treated animals compared to the control group over the course of the 2 week experiment, which suggested that the sustained reduction of body weight might be due to the increase in energy expenditure (ie activation of thermogenesis). Studies on oxygen consumption at a thermoneutral ambient temperature have indicated that increased thermogenesis is initiated by a synergistic interaction between enhanced noradrenaline and 5-HT function in the CNS, 17 an effect mediated via potent noradrenaline and 5-HT reuptake inhibition, which results in a selective activation probably of central sympathetic drive to brown adipose tissue (BAT). However, the precise mechanisms, the receptor types involved and the relative contribution of noradrenaline=5-HT to thermogenesis are not fully understood. Therefore, in the present study, we have determined the effects of sibutramine's metabolite, M2, on colonic temperature, food intake and thermoregulatory behavioural response. We have also attempted to attenuate these responses using various a-and b-adrenergic, 5-HT and D2=D1 receptor antagonists in order to identify the receptor types involved and their relative contribution to both the thermogenic and hypophagic effects of M2.
Materials and methods

Animals
Experiments were performed on female Wistar rats (200 -250 g at the start of the experiment) which were obtained from the colony maintained at St George's Hospital Medical School. Animals were housed in pairs (and individually for the thermoregulatory behaviour experiment) in polypropylene cages with metal grid floors. Polypropylene trays were placed below each cage to detect any food spillage. They were maintained on a conventional pelleted stock diet (Bantin and Kingman, Hull, UK) with free access to water at a room temperature of 21 AE 1 C with a 12:12 h light -dark cycle (lights on at 07:00 h).
Measurement of food intake and body temperature Animals were acclimatized to experimental conditions (such as being handled and colonic temperature measurement) for at least 1 week prior to experimentation. On the test day, animals were randomized to treatment groups. Food intake was monitored during the light phase (2 -8 h) and over the 24 h light -dark cycle. Food hoppers were weighed just before drug administration (09:00 h) and 2, 4.5, 8 and 24 h thereafter. Colonic temperature (Tc) was measured at a room temperature of 21 AE 1 C using a rectal thermocouple probe (Physiotemp, model BAT-12) inserted approximately 6 cm and held until a steady temperature had been recorded. The pretrained rats were allowed to sit unrestrained on the bench during this procedure. Measurements were made at 7 0.5 h prior to the administration of the antagonists or vehicle(s) and then at time 0 (just before giving M2), 0.5, 1.0, 1.5, 2.5, 3.5 and 4.5 h post-M2 administration. Animals were given M2 at a dose of 10 mg=kg, p.o. All antagonists were dosed orally 0.5 h prior to M2.
Measurement of thermoregulatory behavioural response -operant responding for exogenous heat
The test apparatus consisted of a circular 23 cm diameter and 24 cm deep wire-mesh cage. A 4Â5 cm Plexiglas lever mounted on a microswitch protruded 5 cm into the cage and 2 cm above the floor. Two 250 W red bulb infrared lamps were placed at each side of the cage at a 45 angle to the floor and focused on the rat at the lever. The power dissipated by the lamps was set to 300 W, which produced an irradiance of 180 mW=cm 2 . The apparatus was placed in a freezer maintained at 7 8 AE 2 C. A 25 W red incandescent lamp provided low-intensity background illumination. The heat lamps were activated by pressing the lever and remained on as long as the lever was held down. The number of lever presses and the cumulative duration of heat lamp activation (as seconds of heat) were recorded on a computer linked to the apparatus. 18 The animals were closely shaved on the day before the test. They were first trained to press the lever for radiant heat and then given at least six additional tests of 120 min duration so that performance was stable and consistent for two consecutive tests, which took longer than a month in total. Each animal had been tested twice weekly in the previous month with 3 -4 days between tests. On the day of the experiment, four animals were brought to the laboratory in the fed state. They were randomized into four treatment groups. Two of the rats received M2 10 mg=kg (i.p.) and the other two were given saline at 2 ml=kg (i.p.), and they were then returned to their home cage with access to food and water for 3 h. At the end of the 3 h, rats were given either the D2=D1 receptor antagonist ( þ )butaclamol 100 mg=kg or vehicle (i.p.) in a volume of 2 ml=kg, and then returned to 
Statistical analysis
Results are presented as means AE s.e.m. Statistical comparisons of the different treatment groups were made by Student's t-test for paired data and one-way analysis of variance followed by the Dunnett's multiple comparisons test was used for multiple comparisons of differences from control values (see figure legends for details). All probabilities quoted are two-tailed, with P < 0.05 being taken as the level of significance.
Results
Effect of the a 1 -adrenoceptor antagonist, prazosin, and the non-selective 5-HT receptor antagonist, metergoline, on colonic temperature and food intake response to M2 In the control animals, colonic temperature started to decrease at 1.5 h after the start of the experiment and stayed low and stabilized between 2.5 and 4.5 h. Treatment with M2 (10 mg=kg, p.o.) prevented this decrease in body temperature which remained at basal level throughout the experiment (4.5 h; Figure 1a ). The non-selective 5-HT receptor antagonist metergoline (1 mg=kg, p.o.) abolished the effect of M2 on colonic temperature at 1.5 and 2.5 h, and partially antagonized the effect of M2 at the 3.5 and 4.5 h time-points after administration (ie 53% of the M2-induced effect remained). The selective a 1 -adrenoceptor antagonist, prazosin (1 mg=kg, p.o.), significantly reduced colonic temperature below the value of control animals 0.5 h post-M2 administration and completely antagonized the effect of M2 on colonic temperature at 1.5 and 2.5 h following the administration of M2. However, at 3.5 and 4.5 h, prazosin only partially inhibited the effect of M2 (62 and 54% inhibition, respectively). Neither prazosin, nor metergoline, had any effect on colonic temperature when given alone (Figure 1a) .
M2 (10 mg=kg, p.o.) markedly reduced food intake (P < 0.01; Figure 1b) . The animals did not eat for the first 2 h after the administration of M2 and the mean cumulative 
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food intake during the 8 h period was < 1 g compared to 7.8 g for the saline-treated animals (P < 0.01; Figure 1b) . Prazosin (1 mg=kg, p.o.) partially, but significantly antagonized the hypophagia induced by M2 (10 mg=kg, p.o.) as measured at 2, 4.5, 8 and 24 h after drug administration. However, metergoline (1 mg=kg, p.o.) had no effect on M2-induced hypophagia. The saline plus prasozin (1 mg=kg, p.o.)-treated animals consumed more food during the first 4.5 h compared to the saline plus vehicle group, whereas food intake was not affected by saline plus metergoline (1 mg=kg, p.o.) treatment (Figure 1b) .
Effect of the selective a 2 -adrenoceptor antagonist, RS 79948, on colonic temperature and food intake response to M2 The colonic temperature of rats treated with M2 (10 mg=kg, p.o.) plus vehicle or M2 (10 mg=kg, p.o.) plus RS79948 (1 mg=kg, p.o.) was significantly higher than that of salinetreated animals as measured at 2.5, 3.5 and 4.5 h post-M2 administration (P < 0.01; Figure 2a ). The a 2 -adrenoceptor antagonist, RS 79948 (1 mg=kg, p.o.), did not block the effect of M2 (10 mg=kg, p.o.) on colonic temperature. It should be noted that colonic temperature was higher in saline plus RS79948 (1 mg=kg, p.o.)-treated rats than in the saline plus vehicle-treated controls (Figure 2a ). RS79948 (1 mg=kg, p.o.) had no effect on the hypophagia induced by M2 (10 mg=kg, p.o.; (Figure 2b ).
Effect of the non-selective b-adrenoceptor antagonist, propranolol, on colonic temperature and food intake response to M2 Rats treated with M2 (10 mg=kg, p.o.), or M2 plus the nonselective b-adrenoceptor antagonist, propranolol (1 mg=kg, p.o.), had significantly higher colonic temperatures than the saline plus vehicle-treated animals as measured at 2.5, 3.5 and 4.5 h post-M2 administration (Figure 3a) . Although propranolol (1 mg=kg, p.o.) did not block the effect of M2 on colonic temperature, the effect of M2 on colonic temperature was partially inhibited by a higher dose of propranolol (20 mg=kg, p.o.) at 3.5 h (P < 0.05 compared to M2 plus vehicle; Figure 4a ). There was no significant difference between the saline plus vehicle and saline plus propranolol (20 mg=kg, p.o.) treated groups (Figure 4a ). Propranolol (1 and 20 mg=kg, p.o.) did not antagonize the hypophagia induced by M2 (10 mg=kg, p.o.) at any time over the 24 h period (Figures 3b and 4b) . It should be noted that animals treated with saline plus propranolol (20 mg=kg, p.o.) ate less than the saline plus vehicle-treated animals during the first 4.5 h post-M2 (10 mg=kg, p.o.) administration. There was no significant difference between these two groups after 4.5 h (as measured at 8 and 24 h post-M2).
Effect of the D2=D1 receptor antagonist, ( þ )butaclamol, on colonic temperature and food intake response to M2 Colonic temperature was significantly higher in groups of rats treated with both M2 (10 mg=kg, p.o.) plus vehicle and M2 (10 mg=kg, p.o.) plus ( þ )butaclamol (200 mg=kg, p.o.) than in saline plus vehicle controls at 2.5, 3.5 and 4.5 h after M2 administration (P < 0.01). 
Effect of M2 on thermoregulatory behaviour-operant responding for exogenous heat (bar press) The effect of M2 on thermoregulatory behaviour response was tested 3 h after injection of M2 (10 mg=kg, i.p.). Figure 6a shows the effect of M2 on bar press (frequency of heat response) and heat reinforcement (duration of heat response). After an initial intraperitoneal injection dose trial (50, 100, 250, 500 and 1000 mg=kg) with the D2=D1 receptor antagonist ( þ )butaclamol, a dose of 100 mg=kg (i.p.) was chosen to test the effect of D2=D1 receptor antagonist on the thermoregulatory behaviour response to M2, as the saline plus ( þ )butaclamol-treated animals were abnormally inactive or sedated at doses beyond 500 mg=kg, whereas at 50 mg=kg, ( þ )butaclamol did not affect the bar press activity induced by M2 (data not shown). Previous studies 19 have used ( þ )butaclamol at 50 -100 mg=kg 71 (i.v.) to block the effect of ( þ )3-PPP on the activity of zona compacta dopamine neurons. During the 60 min test in the cold ( 7 8 C), Thermogenic effect of Metabolite 2 Y-L Lui et al M2 (10 mg=kg, i.p.) significantly increased the bar press activity (P < 0.01; Figure 6a ) and this increase was manifest throughout the testing period (Figure 6b) . However, as shown in Figure 6c , the total heat reinforcement was significantly less compared to the saline-treated animals. Pretreatment with ( þ )butaclamol (100 mg=kg) abolished the increase in bar-press activity induced by M2 (10 mg=kg; Figure 6a ), but pretreatment with this D 1 =D 2 antagonist did not affect the decrease in heat reinforcement induced by M2 (10 mg=kg) and it remained significantly lower than that of saline-treated animals ( Figure 6c ). There were no significant 
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Y-L Lui et al differences in bar-press activity and heat reinforcement between groups of rats treated with saline plus ( þ )butaclabutaclamol (100 mg=kg) or saline plus vehicle (Figure 6a ). Colonic temperature post-testing increased significantly in all treatment groups after 60 min exposure to cold compared to their pre-test values (Figure 6d ).
Discussion
The results from these experiments demonstrate the potent thermogenic effect of sibutramine's primary amine metabolite, M2, which produced significantly higher colonic temperature over the 4.5 h period. It should be noted that colonic temperature in all saline plus vehicle-treated animals declined gradually over the 4.5 h in the morning when the measurements were made. This decline is normal, and probably reflects a decrease in the diet-induced thermogenesis resulting from the last few nocturnal meals consumed just before the start of the light phase (07:00 h). However, treatment with M2 prevented this decline in colonic temperature. This thermogenic effect of M2 was abolished by the nonselective 5-HT receptor antagonist, metergoline, over the first 2.5 h and it was partially antagonized over the later stage of the experiment (3.5 -4.5 h), which clearly implicates activation of 5-HT mechanisms in M2-induced thermogenesis.
Although the central hypophagic actions of 5-HT have been the subject of extensive investigation, the role of this monoamine in thermogenesis has received considerably less attention. Previous studies have shown that acute injections of 5-HT and its precursor amino acid, tryptophan, directly into the paraventricular nucleus or ventromedial hypothalamus of anaesthetized rats increases the sympathetic firing of nerves supplying BAT. 20 Increased metabolic rate produced by systemic administration of 5-HT has also been reported to be associated with an elevation of BAT activity, BAT blood flow and enhanced activity of the sympathetic nerves supplying BAT. 21 The functional expression of the 5-HT receptors in the hypothalamus provides further evidence for a serotonergic involvement in thermogenesis, as the hypothalamus has long been implicated in the control of feeding and energy balance. 22 As neither M2, nor its parent compound, sibutramine, exhibits affinity for 5-HT receptors 23 (Cheetham, personal communication) , indirect activation of 5-HT receptors subsequent to potent inhibition of 5-HT reuptake is predicted to be partly responsible for the thermogenic property of M2. Metergoline is a non-selective 5-HT receptor antagonist which has high affinity for 5-HT 1 and 5-HT 2 receptors. 24 -26 Therefore, it is not clear which 5-HT receptor subtype(s) is involved in mediating M2-induced thermogenesis. Studies with subtype-selective 5-HT receptor antagonists are required to clarify this issue.
The thermogenic effect of M2 was similarly antagonized by the selective a 1 -adrenoceptor antagonist, prazosin, with abolition of the effect of M2 on colonic temperature during the initial 2.5 h and partial antagonism over the later part of the experiment (3.5 -4.5 h). This result is consistent with the view that activation of a 1 -adrenoceptors consequent to inhibition of noradrenaline reuptake plays an important role in M2-induced thermogenesis. It is interesting that metergoline and prazosin antagonized the thermogenic effect of M2 to a similar extent. Whether metergoline exhibits this effect via blocking both 5-HT 2C and a 1 -adrenoceptors is not known, as it has been reported that metergoline also has moderate affinity for a 1 -adrenoceptors. 27 To investigate the involvement of b 1 -and b 2 -adrenoceptors in M2-induced thermogenesis, a low dose of propranolol (1 mg=kg) was used, as at this dose, propranolol is sufficient to block b 1 -and b 2 -adrenoceptors without affecting the b 3 -subtype. 28 A higher dose of propranolol (20 mg=kg) is required to block the b 3 -adrenoceptor subtype. 28, 29 Interestingly, a low dose of propranolol had no effect on M2-induced increase in colonic temperature, whereas a high dose of propranolol only partially inhibited this effect of M2, which suggests that the b 3 -, but not the b 1 -or b 2 -adrenoceptor subtype, is involved in the M2-induced thermogenesis. This hypothesis is consistent with the finding that b 1 -and b 2 -adrenoceptors are not involved in mediating the increase in oxygen consumption produced by the parent drug, sibutramine. 17 The selective a 2 -adrenoceptor antagonist, RS79948, has high affinity for each of the a 2A -, a 2B -and a 2C -adrenoceptors, whereas RX821002, another widely used a 2 -adrenoceptor antagonist, exhibits higher affinity for a 2A -than the a 2B -and a 2C -subtypes. 30, 31 In the present study, RS79948 alone increased colonic temperature above that of control animals during the second half of the experiment. However, RS79948 neither antagonized nor potentiated the effect of M2 on colonic temperature, indicating that these a 2 -adrenoceptor subtypes are not involved in M2-induced thermogenesis. The thermogenic property of a 2 -adrenoceptor antagonists has previously been shown in other studies where acute, oral yohimbine increased in sympathetic tone and stimulated lipolysis.
32 a 2 -Adrenoceptor agonists, on the other hand, have been reported to decrease body temperature. 33, 34 Taken together, results from the present study suggest that 5-HT, a 1 -and b 3 -adrenoceptors are all involved in M2-induced thermogenesis. Previous studies in this laboratory have demonstrated that stimulation of thermogenesis by sibutramine (determined by oxygen consumption measurements) was due to central activation followed by transmission via autonomic ganglia to the sympathetic nerve endings in BAT, an effect which was attributed to sibutramine's inhibition of both 5-HT and noradrenaline reuptake. 17 It was generally accepted until recently that the extent of badrenoceptor activation and concentration of cAMP in brown fat cells predominantly determine the final outcome of acute sympathetic stimulation of thermogenesis. In contrast, the role of a 1 -adrenoceptors in the acute thermogenic function of BAT has been considered to be minor. However, studies by Zhao et al 35 have indicated that both a b-adrenoceptor-induced increase in cAMP and an a 1 -adrenoceptorinduced increase in cytosolic Ca 2þ level are responsible for noradrenaline-induced thermogenesis. Their data shows that The dopaminergic receptor antagonist ( þ )butaclamol (D2=D1) did not block the effect of M2 on colonic temperature, which suggests that there is no involvement of dopaminergic activation in M2-induced thermogenesis. This hypothesis is further supported by results from the thermoregulatory behaviour study (bar-press) which show that, although dopaminergic activation was responsible for the increased bar-press activity, the D2=D1 receptor antagonist ( þ )butaclamol did not antagonize the decrease in heat reinforcement caused by M2. This also provided further evidence to demonstrate the thermogenic property of M2, such that less heat was required to maintain the body temperature in a cold environment. At present, we are unsure why sibutramine should apparently increase barpressing through a dopaminergic mechanism because the rats displayed no signs of behavioural activation, and we have previously shown that rats are quiescent in the calorimetry chambers after treatment with this dose of M2. 16 Whilst our previous studies have demonstrated that sibutramine increases metabolic activity of BAT by a remarkable 18-fold, 16 this heat production is not the only mechanism that could contribute to the increased core body temperature that is observed in rats after M2 administration; decreased heat loss may also have a significant role, but this possibility has not been investigated.
Although measurement of food consumption during dark phase is more physiological, initial experiments performed during the dark phase proved to be unsuitable for measuring colonic temperature, as the potent hypophagic effect of M2 undermined its thermogenic action. The control animals consumed much more food than the M2-treated rats, and the activation of meal-induced thermogenesis in the control animals was obvious. As the main aim of the present study was to investigate thermogenic mechanisms, it was decided to perform all of the experiments during the light phase. The 5-HT receptor antagonist metergoline had no effect on the M2-induced hypophagia which suggests that 5-HT receptors are not involved in M2-induced hypophagia. This is consistent with the finding by Grignaschi et al 9 that both metergoline and ritanserin (5-HT 2C ) had no effect on sibutramineinduced hypophagia. Jackson et al 7 also found that the 5-HT 2B=2C receptor antagonist, SB200646, did not modify the effect of sibutramine on 2 h food intake. However, they observed a partial blockade of sibutramine-induced hypophagia at 8 h with a low dose of metergoline. The a 2 -adrenoceptor antagonist, RS79948, b-adrenoceptor antagonist, propranolol, and the D2=D1 receptor antagonist, ( þ )butaclamol, all had no effect on hypophagia induced by M2. The only exception was the a 1 -adrenoceptor antagonist, prazosin, which partially antagonized M2-induced hypophagia, indicating that a 1 -adrenoceptor function plays a predominant role in the M2-induced hypophagia, at least under these experimental conditions. These findings are in partial agreement with those reported by Jackson et al 7 where prazosin was found to abolish sibutramine-induced hypophagia, and in addition this suppression of feeding was also partially reversed by the selective b 1 -antagonist, metoprolol. However, in the present study propranolol, at a dose that blocks all three types of b-adrenoceptor, had no effect on M2-induced hypophagia. It should be stressed that the studies by Jackson et al 7 were performed during the dark phase, whereas the experiments reported here were all conducted during the light-phase.
The above data demonstrate that, when given acutely, M2 exerts effects potentially to reduce body weight by decreasing energy intake and increasing energy expenditure. When sibutramine is given chronically, both mechanisms are likely to contribute to the weight loss observed on drug treatment. Thus, the potentiation of resting metabolic rate has been found to increase when sibutramine was given repeatedly over a period of 5 days, 36 whilst some, 12, 16 but not all, 37 investigators have reported an attenuation of sibutramineinduced hypophagia with repeated drug administration. Nevertheless, in all cases, an increasing divergence between the body weight curves of the sibutramine-treated and control groups of rats has been observed with no evidence of tolerance to sibutramine's weight reducing action.
In conclusion, this series of experiments demonstrates that M2 increases colonic temperature (activation of thermogenesis). This increase is probably due to central stimulation of efferent sympathetic activity, which activates thermogenesis. 5-HT, a 1 -and b 3 -adrenergic receptors are probably all involved in mediating M2-induced thermogenesis, whereas a 1 -adrenoceptors are predominantly responsible for its hypophagic effect. These findings are consistent with the known pharmacology of M2 which is a powerful reuptake inhibitor of noradrenaline and 5-HT in rat brain.
